Epigenetics: EpiSwitch Cross-Condition Network Convergence
2 Lammi et al. 2025 — Genome-Wide Association Study of Long COVID
Full Citation:: Lammi V, Nakanishi T, Jones SE, et al., Long COVID Host Genetics Initiative. Genome-wide association study of long COVID. Nature Genetics. 2025;57(6):1402-1417. (Lammi et al. 2025) DOI:: 10.1038/s41588-025-02100-w Key Findings::
- Large multi-ancestry Long COVID GWAS (primary discovery model 11 studies, ~3,018 cases/994,582 broad controls; combined up to 15,950 cases).
- FOXP4 (rs9367106) reached genome-wide significance (OR 1.63).
- Serves as a GWAS input dataset to the Hunter 2026 EpiSwitch cross-condition network analysis.Conclusion: Defines the Long COVID genetic architecture; its genome-wide-significant loci do NOT substantially overlap ME/CFS (DecodeME) loci, contesting gene-level sharing between the two conditions that the network-convergence model seeks to explain at a higher level. Limitations: Long COVID (not strict ME/CFS) population; shared-loci absence here is descriptive, not itself a test of the network-convergence claim; case/control definitions vary across component studies. Certainty Assessment: 0.85 raw × 0.85 (Long COVID population) = discounted ~0.72 (GWAS-level context / gene-overlap contest)
3 Ueland et al. 2025 — Plasma T-Cell Activation/Exhaustion Markers in Persistent Post-COVID Symptoms
Full Citation:: Ueland T, Cox RJ, Michelsen AE, et al. Markers of T cell activation and exhaustion in plasma are associated with persistent symptoms up to 18 months following mild SARS-CoV-2 infection. Frontiers in Immunology. 2025;16:1578208. (Ueland et al. 2025) DOI:: 10.3389/fimmu.2025.1578208 Key Findings::
- Measured soluble (s)CD25, sTIM-3 and sLAG-3 by immunoassay in 170 home-isolated and 53 hospitalized patients followed up to 18 months after COVID-19.
- sLAG-3 elevated in persistent memory complaints at 12–18 months; sCD25 elevated in persistent dyspnea and fatigue; sTIM-3 correlated with antibody titers.
- No relation of these markers to symptoms in hospitalized patients, where disease severity may dominate.Conclusion: Independent (non-vendor) evidence that soluble LAG-3 and other T-cell exhaustion/activation markers track persistent post-viral symptoms — supporting the LAG3/T-cell-exhaustion mechanism Hunter 2026 flags as a shared hub, in a post-viral-fatigue population. Limitations: Post-COVID (mild/moderate, not strict ME/CFS) cohort; single-cohort, plasma surrogate markers; does not validate the cross-condition network-convergence claim itself. Certainty Assessment: 0.55 raw × 0.85 (post-COVID population) = discounted ~0.47 (supporting)
4 Dudova et al. 2025 — The Complex Biological Network Underlying ME/CFS
Full Citation:: Dudova D, Bozhkova M, Petrov S, et al. Insights into the complex biological network underlying Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. International Journal of Molecular Sciences. 2026;27(1):268. (Dudova et al. 2026) DOI:: 10.3390/ijms27010268 Key Findings::
- Reviews ME/CFS as a self-sustaining cycle of interacting immune, metabolic, mitochondrial, neuroendocrine, and gut-brain systems.
- Documents T-cell exhaustion, reduced NK-cell cytotoxicity, abnormal B-cell subsets, ATP/redox imbalance, and HPA-axis hypofunction as interacting network components.Conclusion: Provides an independent single-condition network/systems framing of ME/CFS that conceptually parallels the cross-condition network-convergence model Hunter 2026 extends across ME/CFS, Long COVID, PTSD, RA and MS; does not itself test cross-condition convergence. Limitations: Narrative/systematic review with no primary data; single-condition scope (not cross-disease); Plovdiv group. Certainty Assessment: 0.30 raw × 1.00 (ME/CFS content) = discounted ~0.30 (supporting-framing only)
5 Bubak et al. 2026 — Varicella Zoster Virus Infection
Full Citation:: Bubak AN, Warren-Gash C, Tommasi C, Breuer J, Mahalingam R, Srikanth P, Nagel MA. Varicella zoster virus infection. Nature Reviews Disease Primers. 2026;12(1). (Bubak et al. 2026) DOI:: 10.1038/s41572-026-00735-5 Key Findings::
- Over 90% of people worldwide carry dormant VZV (chickenpox primary infection → lifelong latency in sensory/autonomic nerve cells).
- Reactivation usually presents as shingles, but reactivated VZV can also cause disease WITHOUT a rash (zoster sine herpete / "internal shingles"), mimicking other common diseases.
- VZV reactivation affects sensory nerves, blood vessels, and multiple organs → stroke, cardiovascular events, dementia, Ramsay Hunt syndrome (ear shingles + facial paralysis), vision loss, paralysis, abdominal pain.
- Even with classic shingles, increased risk of stroke/cardiovascular events/dementia.
- Up to one-third of arterial ischemic strokes in children are due to VZV.
- Underrecognized cause of neurological/systemic disease, particularly when rash-less; requires specialized blood/CSF testing.
- Postherpetic neuralgia is a major chronic-pain cause; shingles can recur with undiagnosed immune problems. Antivirals treat VZV; chickenpox + recombinant shingles vaccination reduces risk.Conclusion: The authoritative, comprehensive overview of VZV infection — establishes the rash-less VZV disease (zoster sine herpete) and VZV neurovascular disease concepts that this paper’s ch08 VZV subsection currently lacks. Provides the general-population/mechanism scaffold into which ME/CFS-specific and indirect neurovascular evidence can be placed. Limitations: A disease-primers review (secondary synthesis, no new primary data); covers all-population VZV disease, not ME/CFS specifically; does not establish whether VZV reactivation contributes to ME/CFS. Certainty Assessment: 0.85 raw × 0.75 (general-population/mechanism review) = discounted ~0.64 (supporting scaffold)
6 Shapiro 2009 — Varicella-Zoster Peripheral Ganglia as a Cause of Chronic Fatigue (Hypothesis)
Full Citation:: Shapiro JS. Does varicella-zoster virus infection of the peripheral ganglia cause Chronic Fatigue Syndrome? Medical Hypotheses. 2009;73(5):728-734. (Shapiro 2009) DOI:: 10.1016/j.mehy.2009.04.043 Key Findings::
- Proposes that infection of the peripheral ganglia causes at least some CFS, with neurotropic VZV a likely agent.
- Infection of autonomic ganglia could cause fatigue, postural hypotension, and sleep disturbance; infection of sensory ganglia could cause chronic pain.
- Ganglionic infection produces long-term nerve dysfunction, explaining the chronic course of CFS.
- Models CFS as one manifestation of zoster sine herpete (herpes zoster without rash); notes CFS symptoms overlap shingles except for the painful rash.
- Suggests reduced VZV re-exposure (declining chickenpox) lowers immunity and may explain increased CFS incidence.Conclusion: The single most direct published proposal that rash-less VZV (zoster sine herpete) reactivation in peripheral/autonomic ganglia could produce ME/CFS-like symptoms — the exact novel framing this integration targets. Directly connects to the existing ch08 note that VZV sensory-ganglion neurotropism “may contribute to sensory and autonomic symptoms” in ME/CFS. Limitations: Pure hypothesis essay (Medical Hypotheses, non-peer-reviewed-empirical), single author, no primary data, no direct VZV-reactivation measurement in a CFS cohort, never formally validated. Certainty Assessment: 0.30 raw × 1.00 (conceptual ME/CFS relevance) = discounted ~0.30 (supporting hypothesis only)
7 Halpin et al. 2017 — Increased Anti-Herpesvirus dUTPase Antibodies (incl. VZV) in ME/CFS
Full Citation:: Halpin P, Williams MV, Klimas NG, Fletcher MA, Barnes Z, Ariza ME. Myalgic encephalomyelitis/chronic fatigue syndrome and gulf war illness patients exhibit increased humoral responses to the herpesviruses-encoded dUTPase. Journal of Medical Virology. 2017;89(9):1636-1645. (Halpin et al. 2017) DOI:: 10.1002/jmv.24810 Key Findings::
- ME/CFS (30.91–52.7%) and GWI (29.34%) patients simultaneously produce antibodies against multiple human herpesvirus-encoded dUTPases (EBV, HHV-6, VZV) and/or human dUTPase, vs 17.21% of controls.
- Anti-VZV dUTPase antibodies are one component of the poly-herpesvirus co-reactivation serologic pattern.
- ME/CFS showed highest anti-EBV-dUTPase; GWI higher anti-HHV-6 and anti-human dUTPase.Conclusion: The foundational primary study establishing that VZV (via its dUTPase/ORF8) participates in the poly-herpesvirus co-reactivation serologic signature in ME/CFS — the anchor for the existing ch08 VZV line and the Palomo 2026 72.5% finding already cited. Limitations: Single-lab series (Ariza/Williams/Ohio State + Klimas/Fletcher/Nova Southeastern); cross-sectional serology, no causal inference; diagnostic criteria not specified in abstract; cohort lineage overlaps Palomo2026/Ariza2025 already in corpus. Certainty Assessment: 0.55 raw × 1.00 (ME/CFS cohort) = discounted ~0.55 (supporting) Cohort-overlap note: Ariza/Williams (Ohio State) + Klimas/Fletcher (Nova Southeastern) site lineage — overlaps Palomo2026herpesvirus and Ariza2025polyherpesvirus; count once across the three.
8 Karachaliou et al. 2024 — VZV IgG Elevated in Post-Acute Sequelae of COVID-19
Full Citation:: Karachaliou M, Ranzani O, Espinosa A, et al. Antibody responses to common viruses according to COVID-19 severity and postacute sequelae of COVID-19. Journal of Medical Virology. 2024;96(9):e29862. (Karachaliou et al. 2024) DOI:: 10.1002/jmv.29862 Key Findings::
- Population-based cohort (n=1083 infected individuals) examined plasma IgG/IgA to EBV, CMV, VZV, BK/KI/WU polyomaviruses, RSV, Adv-36 by COVID-19 severity and PASC history.
- Ever PASC, active persistent PASC, and PASC with neuropsychiatric symptoms were associated with higher IgG to EBV early-antigen-diffuse, VZV, and WUPyV — even among those without prior severe COVID-19.Conclusion: Direct serologic evidence that VZV reactivation accompanies long-COVID/post-acute sequelae, including the neuropsychiatric subtype — supporting VZV as part of a post-infectious latent-virus reactivation picture relevant to post-viral fatigue/ME/CFS overlap. Limitations: Serologic (antibody) evidence, not direct VZV detection; PASC self-reported; single cohort; general-population/long-COVID, not strict ME/CFS. Certainty Assessment: 0.65 raw × 0.85 (long-COVID population) = discounted ~0.55 (supporting)
9 Li et al. 2026 — Post-COVID VZV Reactivation as Immune-Threshold Lowering (Consequence)
Full Citation:: Li X, Cheng S, Wang S, Gao K, Bai Y, Li S, Gao M, Guo Y. Post-COVID varicella-zoster virus reactivation: lowering the immunological threshold for latency breakdown. Frontiers in Cellular and Infection Microbiology. 2026;16:1904565. (Li et al. 2026) DOI:: 10.3389/fcimb.2026.1904565 Key Findings::
- Large observational studies report a modest increase in herpes zoster after COVID-19, most consistently after severe disease/hospitalization and within early post-infection windows.
- These associations do not establish direct causation or a population-wide shift of HZ toward younger adults.
- A threshold-lowering interpretation fits better: SARS-CoV-2 infection narrows VZV latency-control reserve via cellular immune disruption, interferon dysregulation, and inflammation.
- Long COVID is a setting of persistent immune dysregulation but is not yet a proven causal framework for VZV disease.Conclusion: Frames VZV reactivation primarily as a CONSEQUENCE of immune disturbance in susceptible hosts — directly relevant to the ch08 “reactivation as consequence vs cause” debate for ME/CFS, and cautions against over-reading a causal/trigger role for VZV in post-viral syndromes. Limitations: Review/opinion (no primary data); interpretive threshold model; post-COVID context, not ME/CFS cohort. Certainty Assessment: 0.45 raw × 0.85 (long-COVID population) = discounted ~0.38 (framing)
10 Fullerton et al. 2025 — Asymptomatic VZV Reactivation in Childhood Arterial Ischemic Stroke (VIPS II)
Full Citation:: Fullerton HJ, Hills NK, Wintermark M, et al. Evidence of varicella zoster virus reactivation in children with arterial ischemic stroke: Results of the VIPS II study. Journal of the American Heart Association. 2025;14(6):e039184. (Fullerton et al. 2025) DOI:: 10.1161/JAHA.124.039184 Key Findings::
- 22-center prospective cohort (n=205 childhood arterial ischemic stroke, 28 days–18 yr; 95 control children).
- 9.8% of AIS children had serologic evidence of recent, ASYMPTOMATIC VZV reactivation at stroke time vs 3.1% of controls; all were clinically silent (no rash).
- Reactivation concentrated in focal cerebral arteriopathy (4/32, 12.5%), not in dissection or moyamoya.Conclusion: High-quality primary evidence that asymptomatic/rash-less VZV reactivation accompanies arterial inflammation and stroke — demonstrating that VZV vasculopathy can proceed without clinical rash, and supporting the ME/CFS-relevant concept that serologically-detectable VZV reactivation need not be clinically visible (rash-less) to be biologically active. Limitations: Childhood stroke population (not ME/CFS); serologic reactivation markers (IgM/IgG) rather than direct virus detection; moderate effect, vaccinated population. Certainty Assessment: 0.75 raw × 0.75 (general-population/mechanism) = discounted ~0.56 (supporting mechanism)
11 Livieratos et al. 2025 — Varicella Zoster Virus and Stroke: An Intricate Relationship
Full Citation:: Livieratos A, Schiro LE, Gogos C, Ntaios G, Akinosoglou K. Varicella zoster virus and stroke: An intricate relationship. Viruses. 2025;17(12):1591. (Livieratos et al. 2025) DOI:: 10.3390/v17121591 Key Findings::
- Mechanism review of VZV-associated neurovascular disease: VZV reactivation from sensory/trigeminal ganglia → infection of cerebral arteries (VZV vasculopathy) → arterial inflammation, stenosis, ischemic stroke, aneurysm, dissection.
- Documents the vascular-inflammatory pathway by which VZV reactivation injures cerebral vasculature.Conclusion: Maps the downstream VZV mechanism (ganglion reactivation → cerebral arterial inflammation) that potentially intersects documented ME/CFS findings on cerebral vasculature and neuroinflammation, even though VZV-stroke epidemiology is not ME/CFS-specific. Complements the Bubak 2026 NRDP review with a dedicated stroke-mechanism synthesis. Limitations: Narrative review (no primary data); general-population VZV-stroke, not ME/CFS; partially redundant with the Bubak 2026 review’s stroke content. Certainty Assessment: 0.50 raw × 0.75 (general-population/mechanism) = discounted ~0.38 (supporting mechanism)
12 Gouda et al. 2026 — Low-Dose Naltrexone: What is the Evidence? A Narrative Review
Full Citation:: Gouda AHK, Aitcheson NEC, Steadman KJ. Low-Dose Naltrexone: What is the Evidence? A Narrative Review. Advances in Therapy. 2026;43(7):2852–2870. (Gouda, Aitcheson, and Steadman 2026) DOI:: 10.1007/s12325-026-03612-5 PMID:: 42060160 Study Design:: Narrative umbrella review (105 human studies; 15 RCTs) across chronic pain, autoimmune/neuroimmune, GI, dermatological, post-infectious, mental-health and oncology indications Key Findings::
- Reviews 105 human LDN studies (≤12.5 mg) across multiple disorders, 15 of them RCTs.
- Central finding: encouraging results from uncontrolled studies rarely survive placebo-controlled testing.
- Most evidence is case reports / small feasibility studies — prone to publication bias and subjective outcomes.
- LDN generally safe, inexpensive, well-tolerated; most studies use 4.5 mg/day.
- Current evidence does not support routine clinical use; a pragmatic role may exist in treatment-resistant cases.
- Calls for larger RCTs with objective endpoints and N-of-1 designs to identify responders.Conclusion: Reinforces the evidence-caution framing already present in ch28 LDN: mechanistic/observational promise has not yet translated into controlled-trial proof. Supports presenting LDN as off-label with limited controlled evidence rather than as established therapy. Limitations: Narrative review (not systematic); cross-disorder synthesis; does not adjudicate ME/CFS-specific controlled evidence (which remains thin). Certainty Assessment: 0.75 raw × 0.75 (general-population, not ME/CFS-specific) = discounted ~0.56 (supporting — review-level evidence framework)
13 Byambasuren et al. 2026 — LDN for Long COVID: Systematic Review and Meta-Analysis
Full Citation:: Byambasuren O, Atkins T, Baptista S, Glasziou P, Chakraborty S. Effect of low-dose naltrexone for long COVID: a systematic review and meta-analysis. BMJ Open. 2026;16(7):e111253. (Byambasuren et al. 2026) DOI:: 10.1136/bmjopen-2025-111253 PMID:: 42463201 Study Design:: Systematic review + meta-analysis Sample Size:: 4 observational pre-post studies (USA, Ireland), n=155 Key Findings::
- No randomized controlled trials of LDN for long COVID identified; only observational pre-post studies met inclusion.
- Pooled pre-post analyses: moderate effects favouring LDN for fatigue (Hedges' g −0.74), brain fog (−0.53), sleep quality (−0.60); large effects for pain (−0.93) and daily functioning (−0.93).
- Heterogeneity ranged 0–62%.
- No serious adverse events in the two studies that assessed safety.
- Certainty of evidence rated LOW.Conclusion: Supports the observational-signal framing in ch28 LDN for post-infectious fatigue — a promising but low-certainty signal from uncontrolled studies. Directly exemplifies why controlled evidence (e.g. the completed-but-unpublished NCT05430152 RCT) is the missing piece. Limitations: No RCTs; observational pre-post designs subject to regression-to-mean and expectation effects; long COVID population (weight 0.85) rather than ME/CFS. Certainty Assessment: 0.60 raw × 0.85 (long COVID) = discounted ~0.51 (supporting — low-certainty observational meta)
14 Wang et al. 2026 — EBV + HLA-DR15 Jointly Drive MS by Myelin Peptide Presentation
Full Citation:: Wang J, Qiu Y, Marti Z, Li F, Wacker M, Oldrati P, et al. EBV infection and HLA-DR15 jointly drive multiple sclerosis by myelin peptide presentation. Cell. 2026;189(2):569–584.e14. (Wang et al. 2026) DOI:: 10.1016/j.cell.2025.12.046 PMID:: 41534530 Study Design:: Mechanistic (in vitro / structural immunology) Key Findings::
- Demonstrates that EBV infection alters antigen processing and presentation on MS-associated HLA-DR15 molecules in infected B cells.
- EBV-infected HLA-DR15 B cells present myelin-derived self-antigens capable of being recognized by autoreactive CD4+ T cells.
- Provides direct mechanistic linkage between infection (EBV), genetically determined HLA-restricted presentation (HLA-DR15), and presentation of CNS self-antigen.Conclusion: Strengthens the infection + HLA-restricted presentation + autoimmunity proof-of-principle for which MS is the canonical model (complementing Lanz 2022 EBNA1/GlialCAM and the HLA-restricted-antigen framework of Georgopoulos 2025). Provides precedent for how EBV could interact with HLA class II to surface self-antigens — a mechanism relevant to ME/CFS only as a testable hypothesis, not a demonstration. Limitations: In vitro / structural (not organism-level); mechanism demonstrated in MS (HLA-DR15), not in ME/CFS; no direct ME/CFS data. Certainty Assessment: 0.65 raw × 0.40 (in vitro) = discounted ~0.26 (supporting mechanism — MS-specific in vitro proof-of-principle)